

1 **Anthocyanin-rich extract mitigates the contribution of the pathobiont genus**

2 ***Haemophilus* in mild-to-moderate ulcerative colitis patients**

3

4 Yannik Zobrist^{1†}, Michael Douberis, MD, DVM, PhD^{2,3,4†}, Luc Biedermann, MD², Gabriel E

5 Leventhal, PhD^{5*}, Gerhard Rogler, MD, PhD^{2*□}

6

7 ¹University of Zurich, Zurich 8006, Switzerland

8 ²Department of Gastroenterology and Hepatology, Department of Medicine, Zurich University Hospital, Zurich 8091,

9 Switzerland

10 ³Gastroklinik, Private Gastroenterological Practice, Horgen 8810, Switzerland

11 ⁴Division of Gastroenterology and Hepatology, Medical University Department, Kantonsspital Aarau, Aarau 5001, Switzerland

12 ⁵PharmaBiome AG, Schlieren 8952, Switzerland

13

14 □Address correspondence to: Prof. Rogler Gerhard, Chief of Department of Gastroenterology and Hepatology, Department of Medicine,

15 Zurich University Hospital, Zurich 8091, Switzerland. E-mail: gerhard.rogler@usz.ch

16

17 **Ethical Considerations**

18 **Financial disclosures and conflicts of interest**

19 MD reports traveling fees from Takeda, FALK, Abbvie as well as consulting fees from Takeda

20 LB reports fees for consulting/advisory board from Abbvie, MSD, Vifor, Falk, Escap, Calypso,

21 Ferring, Pfizer, Shire, Takeda, Janssen, Ewopharma. GR declares consulting fees from Abbvie,

22 Augurix, BMS, Boehringer, Calypso, Celgene, FALK, Ferring, Fisher, Genentech, Gilead,

23 Janssen, MSD, Novartis, Pfizer, Phadia, Roche, UCB, Takeda, Tillots, Vifor, Vital Solutions and

24 Zeller; speaker's honoraria from Astra Zeneca, Abbvie, FALK, Janssen, MSD, Pfizer, Phadia,

25 Takeda, Tillots, UCB, Vifor and Zeller; and grants support from Abbvie, Ardeypharm, Augurix,

26 Calypso, FALK, Flamentera, MSD, Novartis, Pfizer, Roche, Takeda, Tillots, UCB, and Zeller. GEL

27 is an employee and shareholder of PharmaBiome. All other authors declare no conflicts of

28 interest.

29

30 **Abstract**

31 **Objective:** Anthocyanins (AC) have been shown to elicit anti-inflammatory and antioxidant
32 effects in several animal models of colitis. Furthermore, AC lowered biochemical disease
33 activity in our double-blind randomized trial in patients with ulcerative colitis. Here, we
34 report on the changes in the faecal microbiome composition in the patient upon AC
35 exposure in this trial.

36 **Methods:** Ulcerative colitis patients received a 3g daily dose of an AC-rich bilberry extract
37 (ACRE) for eight weeks. We determined the microbiome composition in longitudinal stool
38 samples from 24 patients and quantified the degree of change over time. We also correlated
39 the relative abundances of individual microbial taxa at different time points to faecal
40 concentration measurements of calprotectin.

41 **Results:** Microbiome compositions did not change over time as a result of the intervention,
42 both in terms of alpha and beta diversity. Before the intervention, *Haemophilus*
43 *parainfluenzae* was positively correlated with faecal calprotectin concentrations, and this
44 correlation persisted in placebo-treated subjects throughout the study. In contrast, the
45 correlation between *H. parainfluenzae* and the concentration of faecal calprotectin vanished
46 in ACRE-treated subjects, while the relative abundance of *H. parainfluenzae* did not change.

47 **Conclusion:** Our results suggest that ACRE treatment mitigates the contribution of *H.*
48 *parainfluenzae* to inflammation. Further research is warranted to better comprehend the
49 role of microbial composition in response to medical therapy including AC-rich extract in
50 ulcerative colitis patients.

51

52 **Key words:** ulcerative colitis, intestinal microbiology, IBD, anthocyanin, calprotectin

53

54 **Key messages**

55 **1. What is already known on this topic**

56 Anthocyanins are a promising therapeutic alternative for ulcerative colitis patients
57 given their effect on faecal calprotectin, excellent safety profile, and low costs.

58 **2. What this study adds**

59 The administration of anthocyanin-rich extract to ulcerative colitis patients in a Phase
60 2a study reduced faecal calprotectin concentrations by mitigating the contribution
61 from the pathobiont genus *Haemophilus* but did not affect the overall microbiome
62 composition.

63 **3. How this study might affect research, practice or policy**

64 Our results could aid in targeted treatment of ulcerative colitis patients with
65 anthocyanins, according to individual microbial composition.

66

67 **List of Abbreviations**

68	1.	AC	Anthocyanin
69	2.	ACRE	Anthocyanin Rich Extract
70	3.	ASV	Amplicon Sequence Variants
71	4.	CRP	C Reactive Protein
72	5.	DSS	Dextran Sulphate Sodium
73	6.	GTDB	Genome Taxonomy Database
74	7.	IBD	Inflammatory Bowel Disease
75	8.	IgA	Immunoglobulin A

76	9.	PCA	Principal Component Analysis
77	10.	PCR	Polymerase Chain Reaction
78	11.	SCFA	Short Chain Fatty Acids
79	12.	UC	Ulcerative Colitis
80	13.	5-ASA	5-Aminosalicylic Acid

81

82

83

84 Introduction

85 The incidence and prevalence of inflammatory bowel disease (IBD) and in particular
86 ulcerative colitis (UC) is rising worldwide.[1] The exact pathophysiology of UC remains
87 unknown, with various factors thought to influence the emergence of UC,[2] complicating
88 early detection in cases of suspected IBD, the current non-invasive diagnostic gold standard
89 is determination of faecal calprotectin. The latter, represents a crucial non-degradable
90 leukocyte protein with the best correlation to endoscopic inflammatory indices compared to
91 CRP. It effectively distinguishes among mild, moderate and severe inflammation.[3]

92 Approximately two-thirds of UC patients with mild-to-moderate disease activity can be
93 successfully treated with the anti-inflammatory drug mesalamine (5-ASA). However, non-
94 responders to 5-ASA treatment remain a clinical challenge, with severe cases requiring
95 invasive treatments such as colectomies. Although several other potentially effective
96 medications exist for UC, their typical safety profile is far from ideal, with substantial short
97 and long-term toxicity risks and with high annual costs for newer treatment options such as
98 biologics.[4] Because of this, there is strong interest from IBD patients for complementary
99 therapeutic options that are perceived as “natural and holistic” with fewer side effects.[5]

100 Anthocyanins (AC) a specific type of deglycosylated anthocyanidins, are an alternative
101 herbal remedy for UC. ACs are concentrated in various vegetables and berries, particularly
102 bilberries,[6,7] and are known to have antioxidant and anti-inflammatory effects[7,8] and
103 have thus been preclinically investigated for the treatment of UC. Animal model studies have
104 shown that AC treatment has beneficial effects on dextran sodium sulphate (DSS)-induced
105 colitis. These effects include lower histological scores, reduced cytokine release, less colonic
106 shortening (fibrosis), less weight loss, less hepatosplenomegaly, increased intestinal

107 permeability (which favours bacterial translocation), and lower abundances of pathogenic
108 bacteria compared to control groups.[9,10]

109 Mechanistically, it is feasible that ACs can act on the microbiome in the colon. The
110 majority of ingested ACs bypass absorption in the stomach and small intestine and reach the
111 microbiome-rich colon. There, certain bacteria deglycosylase and metabolize ACs into
112 phenolic acids such as protocatechuic, vanillic, syringic, gallic, or 4-hydroxybenzoic acid.[11]
113 These bacterial fermentation derivatives exhibit beneficial chemoprotective effects due to
114 their intrinsic anti-inflammatory and antioxidative properties.[12] Interestingly, positive
115 effects of AC such as increased short chain fatty acids (SCFA), reduced spleen weight, re-
116 extension of colon length, or ameliorated histological scores could not be achieved or
117 replicated in germ-free mice,[9] suggesting a key role of the microbiome in the AC mode of
118 action Intake of AC also alters the intestinal microbial composition,[10,13] However, it
119 remains unclear whether the observed effects of AC on the human gut microbiome are
120 direct, or indirect via a modulation of the microbial composition and the microbiome's
121 metabolic properties.

122 We recently reported on a multicentre, double-blind, randomized, placebo-controlled
123 phase IIa study to confirm a therapeutic effect of 'AC rich extract' (ACRE) therapy previously
124 observed in a pilot study.[14] In the phase IIa study, we observed that faecal calprotectin
125 concentrations decreased during the treatment phase and subsequently increased again
126 after stopping ACRE therapy.[15] Here, we asked whether the effect of ACRE on faecal
127 calprotectin was mediated by the microbiome. We hypothesized that the effect acted on the
128 microbiome either directly, by inhibiting or promoting certain bacteria, or indirectly, by
129 modulating potential negative effects of certain microbiota. To answer this, we characterized
130 the bacterial microbiome composition in the UC patients throughout the study and

131 particularly investigated whether specific genera might be associated with the observed

132 effect of faecal calprotectin reduction during the intervention.

133

134

135

136

137

138 **Methods**

139 *Ethics*

140 The study was carried out in accordance with principles enunciated in the current
141 version of the Declaration of Helsinki,[16] the guidelines of Good Clinical Practice[17] issued
142 by International Council for Harmonization of Technical Requirements for Pharmaceuticals
143 for Human Use and Swiss regulatory authority's requirements. The project was approved by
144 the Ethics Committee Zurich (BASEC-Nr, 2017-00156).

145

146 *Study design*

147 The full protocol and study design can be found in the supplementary files. Briefly, we
148 included individuals over 18 years of age who had a UC diagnosis for at least three months
149 with a modified Mayo score of 6-12 and a disease activity despite therapy with 5-ASA and
150 steroids. A detailed description of all inclusion and exclusion criteria can be found in the
151 appendix (Supplementary Table 1).

152 Study participants were randomly assigned to either the verum or placebo group in a
153 2:1 ratio. The verum group received a daily dosage of three times 2x500mg of an ACRE
154 provided by Walther Riemer GmbH (Nimbo Green, China), corresponding to 100g dried
155 bilberries or 840mg of anthocyanins per day. The screening phase spanned four weeks,
156 followed by an eight-week intervention period and a subsequent three-week follow-up
157 phase. Three consultations were conducted during the intervention, with stool samples and
158 other relevant data collected at all time points. A detailed study procedure description is
159 available in the Appendix (Supplementary 2).

160

161 *Pre-analytics*

162 The stool was collected with an OMNIgene® GUT kit (DNA Genotek Inc.) and later
163 stored at -20°C until DNA extraction and sequencing (performed by Microsynth AG, Balgach,
164 Switzerland). Amplicon sequencing was performed using Illumina MiSeq paired-ends
165 sequencing technology. The hypervariable region V4 of bacterial 16S rRNA genes was
166 amplified using the primers 515F (GTGCCAGCMGCCGCGGTAA), and 806R
167 (GGACTACHVGGGTWTCTAAT) to generate an approximate amplicon size of 300bp.
168 Multiplexed libraries were constructed with help of the two-step PCR protocol (as
169 recommended by Illumina). The paired-end reads were trimmed of their locus specific
170 primers and subsequently merged to in-silico reconstruct the amplified region resulting in a
171 total of 22.74 million reads, from which Amplicon Sequence Variants (ASVs) were then
172 identified.

173 ASVs were inferred using *Dada2* v1.18.0 with read length filtering set to 250 and 210
174 and maximum expected errors (maxEE) set to 4 and 5 for forward and reverse reads,
175 respectively, and inference performed in "pseudo pool" mode. Read pairs were merged with
176 minimum overlap (minOverlap) of 20, and bimeras were removed using the consensus
177 method. The prepared GTDB r95 taxonomic database for Dada2 (GTDB ref, Dataset Ref) was
178 used for taxonomic annotations via the assignTaxonomy function in Dada2.

179

180 *Statistics*

181 We obtained ASVs from 35 subjects at different study time points. After excluding
182 data from individuals lacking baseline calprotectin measurements or with data available at
183 fewer than 3 study time points, our final cohort comprised of 24 patients, with 17 in the
184 verum group and 7 in the placebo group.

185 Genus-level relative abundances were computed by summing the counts of all ASVs
186 that were assigned to a specific genus and normalizing by all reads. Whenever log-
187 transformed relative abundances were computed, a pseudo count of 1 was added to the
188 read counts.

189 The Shannon diversity, H , was computed at the relevant level of taxonomic resolution
190 (e.g., genus). Subsequently, resulting effective number of genera was computed as the
191 exponential of the Shannon diversity, $exp(H)$, and represents the equivalent number of
192 evenly distributed taxa with the same Shannon diversity. Comparisons between treatment
193 groups were performed for each timepoint individually using Wilcoxon signed-rank tests.

194 We computed the Aitchison distance, i.e. the magnitude of change in microbiome
195 composition between the centre-log-ratio transformed relative abundances. Comparisons
196 between groups or timepoints were performed using Wilcoxon signed-rank tests.

197 The change of individual taxa (e.g., genera) over time following baseline was
198 estimated from a linear mixed model of the log₁₀-transformed relative abundances with
199 treatment as a fixed effect and by treating timepoint as an integer including a random slope
200 for the effect of time and a random intercept for each individual.

201 To quantify the association of individual microbiome genera with calprotectin levels
202 prior to the intervention, we performed individual linear mixed model regressions of the
203 log₁₀-transformed calprotectin concentrations on the log₁₀-transformed relative abundances
204 for those genera that were detected in at least 50% of the samples. To capture potential
205 variability in the microbiome over time, we used both the screening and baseline
206 abundances and accounted for subject identity as a random effect. We adjusted the p-values
207 using the method of Benjamini-Hochberg.

208

209


210 **Results**

211 We previously reported that ACRE treatment reduced faecal calprotectin
212 concentrations resulting in a significantly lower concentration in the ACRE group compared
213 to the placebo group by the third visit,[15] but not at earlier visits. In order to better
214 understand the dynamics of how the faecal calprotectin over time, we estimated a per-
215 subject change in faecal calprotectin using a linear mixed model. Faecal calprotectin
216 decreased steadily during treatment in the ACRE group ($p = 0.0243$), but did not change in
217 the placebo-treated patients ($p = 0.427$; Supplementary Figure 1). The concentration
218 subsequently increased again following the end of the treatment. This suggests that ACRE
219 treatment might act gradually and consistently.

220 A gradual action of ACRE on the microbiome might manifest in different ways. First, in
221 a direct way, ACRE treatment might gradually shift the microbiome composition over time
222 away from a pro-inflammatory state. Second, in an indirect way, ACRE treatment might not
223 affect the microbiome composition *per se*, but instead mitigate any pro-inflammatory impact
224 of the microbiome. In the first case, we would expect the microbiome composition to
225 gradually change during ACRE treatment—but not during placebo treatment, and in the
226 second case we would expect the microbiome to not change in either group. We did not
227 observe any evidence of a systematic change in microbiome composition in either treatment
228 group. We quantified the change in microbiome composition in terms of alpha and beta
229 diversity. For alpha diversity, we modelled the change in the effective number of genera
230 using the same linear mixed model approach as for faecal calprotectin with a treatment-
231 specific slope and common intercept at baseline, and per-subject random slopes and

232 intercepts. Alpha diversity did not change over time in either treatment group (Figure 1a).
233 For beta diversity, we quantified the degree of change in terms of the Aitchison distance
234 between Baseline and Visit3 for each subject, and compared this to the distribution of
235 distances between subjects at Baseline. The Aitchison distance between Baseline and Visit3
236 was not significantly different in the ACRE and placebo groups ($p = 0.697$, Figure 1c), implying
237 that individual patients mostly retained their microbiome composition during treatment
238 (Figure 1b). Taken together, we do not find evidence that ACRE treatment modifies the
239 microbiome composition directly.

240



241

242 **Figure 1. Microbiota composition is not affected by ACRE treatment.** a. Microbiome alpha
243 diversity does not change during treatment. Blue squares and grey circles show the alpha
244 diversities at different timepoints in the study for the ACRE and placebo groups, respectively.
245 Symbols from the same patients are connected by lines. The dashed lines show the
246 estimated slopes from a linear mixed effects model that are not significantly different from
247 zero ($p = 0.260$ and $p = 0.215$). b. Principal component analysis (PCA) of the faecal microbiota
248 based on genus consumption over time. Each path represents an individual patient.
249 (baseline: filled shapes, follow-up: open shapes). c. Aitchison distances between subjects at
250 baseline, or between Baseline and Visit3 for the Bilberry and Placebo groups. ns = non-
251 significant, *** = p value < 0.00005 .

252

253


254 Given that ACRE treatment does not modify microbial composition directly, we next
255 turn to the second option where ACRE acts indirectly, implying that there are certain
256 microbiota characteristics that promote inflammation that are then mitigated by ACRE
257 treatment. To identify such characteristics, we analysed whether certain genera correlated
258 with faecal calprotectin concentrations before the start of the intervention. To increase
259 statistical power, we grouped the screening and baseline samples together but accounted for
260 subject identity as a random effect.

261 We identified 13 genera whose relative abundances were either positively or
262 negatively associated with calprotectin levels prior to the intervention (Figure 2a). Of these,
263 only two—*Haemophilus* and *Parasutterella*—remained significant after correction for
264 multiple testing at a false-discovery rate below 0.1 (Supplementary Table 3). Increasing
265 relative abundances of the genus *Haemophilus* were associated with higher concentrations
266 of faecal calprotectin ($p_{\text{adj}} = 0.053$, conditional $R^2 = 0.43$), whereas higher relative
267 abundances of *Parasutterella* were associated with lower concentrations of calprotectin (p_{adj}
268 = 0.053, conditional $R^2 = 0.52$) (Figure 2b).

269 This analysis identifies *Haemophilus* abundance as a potential contributor to
270 inflammation and conversely *Parasutterella* as a potential mitigator of inflammation in the
271 subjects before initiating treatment. We presumed that if these contributions were robust,
272 then they should persist throughout the study in the placebo-treated individuals in which we
273 do not expect any modulation of the interaction between microbiome and inflammation.

274

275



276

277 **Figure 2. Genera associated with high/low fecal calprotectin concentration prior to the**
278 **intervention. a.** Volcano plot of the regression slopes and their individual p-values. Genera
279 with $p < 0.05$ are labelled. **b.** Visualization of the relationship between relative abundance (x-
280 axis) and fecal calprotectin concentrations for the two genera with a false discovery rate <
281 0.1. Samples from the same individual at Screening (circles) and Baseline (squares) are
282 connected with a line.

283

284

285 The association of *Haemophilus* and faecal calprotectin persisted in the placebo group
286 throughout the intervention, while the association for *Parasutterella* did not. We used all
287 sampling points after the start of the intervention, i.e., visits 1-3 and follow-up and
288 accounted for subject identity as a random intercept. *Haemophilus* relative abundance
289 remained significantly correlated with faecal calprotectin concentrations in the placebo
290 group after the start of the intervention ($p = 0.0347$, conditional $R^2 = 0.367$, Supplementary
291 Figure 2). In contrast, the negative correlation between *Parasutterella* Relative abundance
292 and faecal calprotectin was not significant after the start of the intervention ($p = 0.673$,
293 conditional $R^2 = 0.28$). This suggests that *Haemophilus* might indeed contribute directly to
294 inflammation.

295 We hypothesized that if ACRE directly exerts an influence on the microbiota, for
296 instance by depleting *Haemophilus* abundance, then a correlation between *Haemophilus* and

297 faecal calprotectin would be expected to remain in the ACRE group, with a potential overall
298 decrease in *Haemophilus* abundance. Alternatively, if ACRE were to modify the mechanism
299 with which *Haemophilus* contributes to inflammation, then we would not expect an effect
300 on *Haemophilus* abundance but rather that there would nevertheless be a decrease in faecal
301 calprotectin concentration.


302 To test these hypotheses, we first investigated whether the relative abundance of
303 *Haemophilus* changed during ACRE treatment. Second, we investigated whether the
304 relationship between the abundance of *Haemophilus* and faecal calprotectin concentration
305 remained in the ACRE group after the start of the intervention.

306 ACRE treatment did not impact *Haemophilus* abundance but did negate the
307 association between *Haemophilus* and faecal calprotectin. The estimated change in
308 *Haemophilus* abundance over time in the ACRE group was not significantly different from
309 zero ($p = 0.345$, Figure 3). However, faecal calprotectin was no longer significantly associated
310 with *Haemophilus* relative abundance after the start of the intervention ($p = 0.422$,
311 conditional $R^2 = 0.42$) (Figure 4). Closer inspection of the ASVs that were identified as
312 *Haemophilus* in our data revealed only a single ASV that mapped with 100% identity to the
313 strain *Haemophilus parainfluenzae* ATCC 33392. Taken together, these results indicate that
314 ACRE treatment modifies the interaction between *Haemophilus parainfluenzae* and
315 inflammation, rather than by directly decreasing *Haemophilus* abundance.

316

317

318



319


320 **Figure 3. *Haemophilus* relative abundance remains stable during treatment.** Each small
321 circle shows the relative abundance of the genus *Haemophilus* in either the placebo group
322 (grey) or ACRE group (blue). The large circles show the mean within the groups for each
323 timepoint. The dashed lines show the estimated regression slope of \log_{10} relative abundance
324 over time.

325

326

327

328



329

330 **Figure 4. *Haemophilus* relative abundance is not significantly correlated with faecal**
331 **calprotectin during ACRE treatment.** Each point corresponds to a sample from a patient at
332 visit 1 (circles), visit 2 (triangles), or visit 3 (squares). The dashed line shows the estimated
333 regression slope from a linear mixed model with subject as a random effect.

334

335

336

337

339 Discussion

340 In our study we aimed to investigate to what degree the previously observed effect of
341 ACRE treatment on lowering faecal calprotectin concentrations in a clinical study in subjects
342 with mild to moderate UC was linked to a modulation of the microbiome in these subjects. .
343 Unexpectedly, we did not observe any substantial shifts in microbiome composition induced
344 by ACRE treatment. Instead, we observed that ACRE treatment mitigated the association
345 between the abundance of the genus *Haemophilus* in the faecal microbiome and the faecal
346 calprotectin concentration. Prior to initiating the study, patients with higher abundances of
347 *Haemophilus* also had higher concentrations of faecal calprotectin and this correlation
348 persisted in the placebo-treated patients. In contrast, the correlation vanished during ACRE
349 treatment. Therefore, ACRE administration did not reduce faecal calprotectin concentrations
350 by directly modulating the microbial composition, but rather by indirectly affecting the
351 proinflammatory mechanisms of bacterial taxa such as *Haemophilus*.

352 The observation that treatment with AC did not affect the microbiome composition is
353 unexpected based on previous mouse studies in the literature of AC impacting microbiome
354 alpha and beta diversity in UC. Two studies observed an increased Shannon index and a
355 significant beta diversity shift after ingesting 200mg/kg AC for 7 or 17 days,
356 respectively.[10,18] Another four-week study with daily intake of 3.47mg suggested a
357 potential increase in alpha diversity post-anthocyanin intake.[19] However, these studies
358 were performed in mice with DSS-induced colitis, used sources of AC other than bilberries
359 that may impact the effect,[20] and had higher daily doses per kg body weight (173-
360 200mg/kg) compared to our study (ca. 11.8mg/kg; assuming an average European weight of
361 71kg).

362 The genus *Haemophilus* has previously been reported to be increased in abundance
363 in IBD patients.[21–24] The positive correlation we observed between the relative
364 abundance of *Haemophilus* and faecal calprotectin concentrations is in line with a previous
365 work that found an association of *Haemophilus* with more severe disease.[25]

366 Consistent with our results, two studies have reported an increased presence of
367 *Haemophilus spp.* in UC patients that is particularly pronounced in active stages.[26,27] Thus,
368 emerging evidence suggests that *Haemophilus spp.* may be considered as a potentially
369 pathogenic genus for UC. Moreover, studies have demonstrated that *Haemophilus*
370 *parainfluenza* exhibits strong IgA coating in individuals with UC.[28] IgA, the predominant
371 dimeric antibody in the intestinal mucosa, plays a crucial role in coating and neutralizing
372 pathogens. IgA coating is also observed in endogenous microbiota, though to a lesser extent
373 than with pathogens.[29] Given that certain genera influencing UC severity share similarities
374 with pathogens,[30] Palm et al. and Shapiro et al. suggest pathogenic microbiota may be
375 more heavily coated with IgA.[31,32] Furthermore, more active UC is associated with
376 increased IgA coating and higher faecal IgA levels[33] and on the other hand mice with
377 elevated IgA levels and therefore higher amount of coated bacteria demonstrate greater
378 resistance to DSS-induced murine colitis.[34] Finally, blueberry ingestion is linked to
379 increased IgA secretion.[35,36] In summary, it is reasonable to hypothesize that IgA secretion
380 is increased by higher inflammatory activity or pathogenic microbes, thus coating the more
381 pathogenically active microbiota trying to provide control of colitis. AC, in turn, seem to
382 facilitate IgA production, exerting their potentially anti-inflammatory effect on UC. ACRE may
383 stimulate IgA secretion resulting in a more intensive coating of pathobiont *Haemophilus*,
384 thereby reducing its proinflammatory potential. However, other potential anti-inflammatory

385 mechanisms of ACRE via the microbiome are conceivable, such as promoting beneficial SCFA
386 production, reducing colonic shortening, or enhancing epithelial barriers.[9,13]

387 The observation of a clinically meaningful decrease in a key biochemical parameter
388 that is linked to disease activity in UC suggests that AC might be considered as a viable
389 treatment option in UC that warrants further evaluation. While it is unlikely that
390 anthocyanins exert their effects exclusively by mitigating the proinflammatory potential of
391 *Haemophilus spp.*, their potential benefits may be more pronounced in individuals with
392 higher *Haemophilus spp.* abundance in their intestinal microbiome. Additionally, probiotic
393 therapies might prove valuable in reducing pathobionts such as *Haemophilus spp.* in UC
394 patients, fostering a more favourable microbial microenvironment for the disease.
395 Nevertheless, larger studies are essential to reach accumulation of positive evidence and
396 secondarily a consensus on the composition of the microbiota and its analysis in order to
397 take a step towards personalized medicine, especially with complementary options such as
398 ACRE.

399 A particular strength of our study is the randomized double-blind design with a novel
400 intervention among the first to investigate the impact of a high-dose anthocyanin
401 intervention on the microbiome composition in UC patients. While there are already some
402 investigations on this topic in animal models,[9,10,13,18–20] this is to the best of our
403 knowledge the first human data. Another strength of our study is that we repeated
404 assessments of the key parameters, microbiome composition and faecal calprotectin
405 concentration, over time for the same subjects that enables us to account for some of the
406 intra-individual variability.

407 Several limitations of our study have to be acknowledged. Firstly, our sample size
408 comprising of only 24 patients is rather small and for this reason we have taken care that our

409 statistical inferences are appropriate. A further limitation that is shared by most other
410 microbiome studies is that our work considers only relative abundances of microbial taxa and
411 focuses primarily on faecal calprotectin. We did not investigate other related parameters
412 such as the microbial metabolome or immunologic factors like intestinal IgA production.
413 Finally, we exclusively focused on bacterial taxa of the intestinal microbiota and did not take
414 other microbes into account, such as fungi, viruses, or protozoa.

415 In conclusion, we provide evidence that the anti-inflammatory effect of the ACRE
416 intervention was not mediated via a relevant modulation of the microbiome, as originally
417 thought, but rather via a regulation of the pro-inflammatory effect of its pathobionts such as
418 *Haemophilus parainfluenzae*. Whether this effect is directly caused by the administered AC
419 or rather by their degradation products after metabolization by the microbiome remains
420 unclear. Regarding the intake of AC, the exact interaction of anthocyanins and the
421 microbiome in UC has not yet been clarified and remains vague. Which biochemical and
422 physiological links are involved and what might be the overall effect on the disease needs to
423 be further investigated.

424

425 **Acknowledgements**

426 The authors wish to thank all the patients for their cooperation as well as their families
427 for their support during this endeavour.

428

429 **Ethical Considerations**

430 **Financial disclosures and conflicts of interest**

431 MD reports traveling fees from Takeda, FALK, Abbvie as well as consulting fees from Takeda

432 LB reports fees for consulting/advisory board from Abbvie, MSD, Vifor, Falk, Escap, Calypso,
433 Ferring, Pfizer, Shire, Takeda, Janssen, Ewopharma. GR declares consulting fees from Abbvie,
434 Augurix, BMS, Boehringer, Calypso, Celgene, FALK, Ferring, Fisher, Genentech, Gilead,
435 Janssen, MSD, Novartis, Pfizer, Phadia, Roche, UCB, Takeda, Tillots, Vifor, Vital Solutions and
436 Zeller; speaker's honoraria from Astra Zeneca, Abbvie, FALK, Janssen, MSD, Pfizer, Phadia,
437 Takeda, Tillots, UCB, Vifor and Zeller; and grants support from Abbvie, Ardeypharm, Augurix,
438 Calypso, FALK, Flamentera, MSD, Novartis, Pfizer, Roche, Takeda, Tillots, UCB, and Zeller. GEL
439 is an employee and shareholder of PharmaBiome. All other authors declare no conflicts of
440 interest

441

442

443 **References**

- 444 1 Ng SC, Shi HY, Hamidi N, *et al.* Worldwide incidence and prevalence of inflammatory
445 bowel disease in the 21st century: a systematic review of population-based studies.
446 *The Lancet.* 2017;390:2769–78. doi: 10.1016/S0140-6736(17)32448-0
- 447 2 Ungaro R, Mehandru S, Allen PB, *et al.* Ulcerative colitis. *The Lancet.* 2017;389:1756–
448 70. doi: 10.1016/S0140-6736(16)32126-2
- 449 3 Schoepfer AM, Beglinger C, Straumann A, *et al.* Ulcerative colitis: Correlation of the
450 Rachmilewitz Endoscopic Activity Index with fecal calprotectin, clinical activity, C-
451 reactive protein, and blood leukocytes. *Inflamm Bowel Dis.* 2009;15:1851–8. doi:
452 10.1002/ibd.20986
- 453 4 Rogler G, Bernstein CN, Sood A, *et al.* Role of biological therapy for inflammatory
454 bowel disease in developing countries. *Gut.* 2012;61:706–12. doi: 10.1136/gutjnl-
455 2011-300613
- 456 5 Langhorst J, Anthonisen IB, Steder-Neukamm U, *et al.* Patterns of complementary and
457 alternative medicine (CAM) use in patients with inflammatory bowel disease:
458 Perceived stress is a potential indicator for CAM use. *Complement Ther Med.*
459 2007;15:30–7. doi: 10.1016/j.ctim.2006.03.008
- 460 6 Wing-kwan Chu, Sabrina C. M. Cheung, Roxanna A. W. Lau IFFB. *Chapter 4: Bilberry*
461 *(Vaccinium myrtillus L.). 2.* Boca Raton: CRC Press/Taylor & Francis, Boca Raton (FL)
462 2011.
- 463 7 He J, Monica Giusti M. Anthocyanins: Natural colorants with health-promoting
464 properties. *Annu Rev Food Sci Technol.* 2010;1:163–87. doi:
465 10.1146/annurev.food.080708.100754

- 466 8 Kent K, Charlton K, Roodenrys S, *et al.* Consumption of anthocyanin-rich cherry juice
467 for 12 weeks improves memory and cognition in older adults with mild-to-moderate
468 dementia. *Eur J Nutr.* 2017;56:333–41. doi: 10.1007/s00394-015-1083-y
- 469 9 Li S, Wang T, Fu W, *et al.* Role of Gut Microbiota in the Anti-Colitic Effects of
470 Anthocyanin-Containing Potatoes. *Mol Nutr Food Res.* 2021;65:1–14. doi:
471 10.1002/mnfr.202100152
- 472 10 Mo J, Ni J, Zhang M, *et al.* Mulberry Anthocyanins Ameliorate DSS-Induced Ulcerative
473 Colitis by Improving Intestinal Barrier Function and Modulating Gut Microbiota.
474 *Antioxidants.* 2022;11. doi: 10.3390/antiox11091674
- 475 11 Tian L, Tan Y, Chen G, *et al.* Metabolism of anthocyanins and consequent effects on the
476 gut microbiota. *Crit Rev Food Sci Nutr.* 2019;59:982–91. doi:
477 10.1080/10408398.2018.1533517
- 478 12 Farombi EO, Adedara IA, Awoyemi O V., *et al.* Dietary protocatechuic acid ameliorates
479 dextran sulphate sodium-induced ulcerative colitis and hepatotoxicity in rats. *Food*
480 *Funct.* 2016;7:913–21. doi: 10.1039/c5fo01228g
- 481 13 Li J, Wu T, Li N, *et al.* Bilberry anthocyanin extract promotes intestinal barrier function
482 and inhibits digestive enzyme activity by regulating the gut microbiota in aging rats.
483 *Food Funct.* 2019;10:333–43. doi: 10.1039/c8fo01962b
- 484 14 Biedermann L, Mwinyi J, Scharl M, *et al.* Bilberry ingestion improves disease activity in
485 mild to moderate ulcerative colitis - An open pilot study. *J Crohns Colitis.* 2013;7:271–
486 9. doi: 10.1016/j.crohns.2012.07.010
- 487 15 Biedermann L, Doulberis M, Schreiner P, *et al.* A Multi-Center Randomized, Double-
488 Blind, Placebo Controlled, Parallel Group, Phase IIa Study to Evaluate the Efficacy,
489 Safety and Tolerability of an Anthocyanin Rich Extract (ACRE) in Patients with
490 Ulcerative Colitis. *medRxiv.* 2024;2024.07.19.24310589. doi:
491 10.1101/2024.07.19.24310589
- 492 16 Review C, Communication S, Principles G. World Medical Association Declaration of
493 Helsinki: ethical principles for medical research involving human subjects. *J Am Coll*
494 *Dent.* 2014;81:14–8. doi: 10.1093/acprof:oso/9780199241323.003.0025
- 495 17 European Medicines Agency (EMA). Guideline Good Clinical Practice E6(R2).
496 *Committee for Human Medicinal Products.* 2018;6:1–68.
- 497 18 Tan C, Wang M, Kong Y, *et al.* Anti-inflammatory and intestinal microbiota modulation
498 properties of high hydrostatic pressure treated cyanidin-3-glucoside and blueberry
499 pectin complexes on dextran sodium sulfate-induced ulcerative colitis mice. *Food*
500 *Funct.* 2022;4384–98. doi: 10.1039/d1fo03376j
- 501 19 Moon HJ, Cha YS, Kim KA. Blackcurrant Alleviates Dextran Sulfate Sodium (DSS)-
502 Induced Colitis in Mice. *Foods.* 2023;12. doi: 10.3390/foods12051073
- 503 20 Wu B, Cox AD, Chang H, *et al.* Maize near-isogenic lines with enhanced flavonoids
504 alleviated dextran sodium sulfate-induced murine colitis via modulation of the gut
505 microbiota. *Food Funct.* 2023;14:9606–16. doi: 10.1039/d3fo02953k
- 506 21 Gevers D, Kugathasan S, Denson LA, *et al.* The Treatment-Naive Microbiome in New-
507 Onset Crohn's Disease. *Cell Host Microbe.* 2014;15:382–92. doi:
508 10.1016/j.chom.2014.02.005
- 509 22 Lloyd-Price J, Arze C, Ananthakrishnan AN, *et al.* Multi-omics of the gut microbial
510 ecosystem in inflammatory bowel diseases. *Nature.* 2019;569:655–62. doi:
511 10.1038/s41586-019-1237-9

- 512 23 Kansal S, Catto-Smith AG, Boniface K, *et al.* The Microbiome in Paediatric Crohn's
513 Disease—A Longitudinal, Prospective, Single-Centre Study. *J Crohns Colitis*.
514 2019;13:1044–54. doi: 10.1093/ecco-jcc/jjz016
- 515 24 Putignani L, Oliva S, Isoldi S, *et al.* Fecal and mucosal microbiota profiling in pediatric
516 inflammatory bowel diseases. *Eur J Gastroenterol Hepatol*. 2021;33:1376–86. doi:
517 10.1097/MEG.0000000000002050
- 518 25 Schirmer M, Denson L, Vlamakis H, *et al.* Compositional and Temporal Changes in the
519 Gut Microbiome of Pediatric Ulcerative Colitis Patients Are Linked to Disease Course.
520 *Cell Host Microbe*. 2018;24:600-610.e4. doi: 10.1016/j.chom.2018.09.009
- 521 26 Barberio B, Facchin S, Patuzzi I, *et al.* A specific microbiota signature is associated to
522 various degrees of ulcerative colitis as assessed by a machine learning approach. *Gut*
523 *Microbes*. 2022;14:1–12. doi: 10.1080/19490976.2022.2028366
- 524 27 Čipčić Paljetak H, Barešić A, Panek M, *et al.* Gut microbiota in mucosa and feces of
525 newly diagnosed, treatment-naïve adult inflammatory bowel disease and irritable
526 bowel syndrome patients. *Gut Microbes*. 2022;14:1–21. doi:
527 10.1080/19490976.2022.2083419
- 528 28 Shapiro JM, de Zoete MR, Palm NW, *et al.* Immunoglobulin A Targets a Unique Subset
529 of the Microbiota in Inflammatory Bowel Disease. *Cell Host Microbe*. 2021;29:83-
530 93.e3. doi: 10.1016/j.chom.2020.12.003
- 531 29 Pabst O. New concepts in the generation and functions of IgA. *Nat Rev Immunol*.
532 2012;12:821–32. doi: 10.1038/nri3322
- 533 30 Chow J, Tang H, Mazmanian SK. Pathobionts of the gastrointestinal microbiota and
534 inflammatory disease. *Curr Opin Immunol*. 2011;23:473–80. doi:
535 10.1016/j.coi.2011.07.010
- 536 31 Palm NW, De Zoete MR, Cullen TW, *et al.* Immunoglobulin A coating identifies
537 colitogenic bacteria in inflammatory bowel disease. *Cell*. 2014;158:1000–10. doi:
538 10.1016/j.cell.2014.08.006
- 539 32 Shapiro JM, Cho JH, Sands BE, *et al.* Bridging the gap between host immune response
540 and intestinal dysbiosis in inflammatory bowel disease: Does immunoglobulin a mark
541 the spot? *Clinical Gastroenterology and Hepatology*. 2015;13:842–6. doi:
542 10.1016/j.cgh.2015.02.028
- 543 33 Lin R, Chen H, Shu W, *et al.* Clinical significance of soluble immunoglobulins A and G
544 and their coated bacteria in feces of patients with inflammatory bowel disease. *J*
545 *Transl Med*. 2018;16:1–15. doi: 10.1186/s12967-018-1723-0
- 546 34 Gupta S, Basu S, Bal V, *et al.* Gut IgA abundance in adult life is a major determinant of
547 resistance to dextran sodium sulfate-colitis and can compensate for the effects of
548 inadequate maternal IgA received by neonates. *Immunology*. 2019;158:19–34. doi:
549 10.1111/imm.13091
- 550 35 Liu X, Wang L, Zhuang H, *et al.* Promoting intestinal IgA production in mice by oral
551 administration with anthocyanins. *Front Immunol*. 2022;13. doi:
552 10.3389/fimmu.2022.826597
- 553 36 Taira T, Yamaguchi S, Takahashi A, *et al.* Dietary polyphenols increase fecal mucin and
554 immunoglobulin A and ameliorate the disturbance in gut microbiota caused by a high
555 fat diet. *J Clin Biochem Nutr*. 2015;57:212–6. doi: 10.3164/jcfn.15-15
556
557

558 **Supplementary Tables**

Inclusion Criteria	Exclusion Criteria
Male or female ≥ 18 years of age	Acute fulminant UC and/or signs of systemic toxicity
Established diagnosis of UC, with minimum time from diagnosis of ≥ 3 months	UC limited to the rectum (disease which extends < 15 cm above the anal verge)
Moderately at least left sided UC (disease should extend 15cm or more above the anal verge). Disease severity determined by a Modified Mayo Score of 6 to 12 with an endoscopic sub score ≥ 2 assessed by central reading of endoscopy performed at screening visit and no other individual sub score < 1	Suspicion of differential diagnosis such as: Crohn's, enterocolitis, ischaemic colitis, radiation colitis, indeterminate colitis, infectious colitis, diverticular disease, associated colitis, microscopic colitis, massive pseudopolypsis or non-passable stenosis
Current oral or rectal 5-ASA/SP use or a history of oral or rectal 5-ASA/SP use	Serious active infection or current history of active infection
	Gastrointestinal infections including positive Clostridium difficile stool assay
Current steroids use or history of steroids dependency, refractory, or intolerance, including no steroids treatment due to earlier side-effects (only one of the steroids criteria have to be fulfilled, see definition in European Crohn's and Colitis organization (ECCO) guidelines)	History or presence of any clinically significant disorder that, in option of the investigator, could impact on patient's possibility to adhere to the protocol and protocol procedures or would confound the study result or compromise patient safety
One of the following points must be fulfilled:	History of malignancy, except for:
<ul style="list-style-type: none"> Active disease despite induction therapy with 5-ASA agents where adequate therapy is considered with an oral 5-ASA (mesalazine 2-4.8g/day, sulfasalazine 4-6g/day) administered for at least 2 weeks. Topical treatment with 5-ASA may have been attempted but this is not a prerequisite for inclusion in the study Intolerance to oral 5-ASAs or azathioprine Active disease despite a thiopurine (adequately dosed according to treatment guidelines, such as 2-3 mg/kg for azathioprine) or methotrexate administered for at least 12 weeks Active disease despite treatment with biologicals or calcineurin inhibitors 	<ul style="list-style-type: none"> Treated (cured) basal cell or squamous cell in situ carcinoma Treated (cured) cervical intraepithelial neoplasia Carcinoma in situ of the cervix with no evidence of recurrence within the previous 5 years prior to the screening visit
	Presence or history of underlying metabolic, endocrine, hematologic, pulmonary, cardiac, blood, renal, hepatic, infectious, psychiatric or any medically unstable condition as assessed by the primary treating physician which, in the option of the investigator, would place the subject at unacceptable risk for participation in the study
	Significant illness within the two weeks prior to dosing or any active infection or medical condition that may require treatment or therapeutic intervention during the study
	Known history of alcohol abuse, chronic liver or biliary disease
	History or presence of a significant renal disease
Allowed to receive a therapeutic dose of following UC drugs during the study:	Long term treatment with antibiotics or non-steroidal anti-inflammatory drugs (NSAIDs) within two weeks prior to screening (one short treatment regime for antibiotics and occasional use of NSAIDs are allowed)
<ul style="list-style-type: none"> Oral steroids therapy (≤ 30mg prednisone or equivalent/day) providing that the dose has been stable for 2 weeks prior to baseline Oral or rectal MMX Budesonide therapy (9mg/day) initiated at least 8 weeks before baseline Oral or rectal 5-ASA/SP compounds, providing that the dose has been stable for 2 weeks before baseline visit AZA/6-MP providing that the dose has been stable for 8 weeks prior to baseline and been initiated at least 2 months before screening TNF inhibitors (Infliximab, Adalimumab or Golimumab) are allowed, providing that the dose is stable for at least 2 months prior to baseline and during the study treatment period Vedolizumab and Tofacitinib is allowed, providing that the dose is stable for at least 2 months prior to baseline and during the study treatment period 	Antibiotics within the last week prior to randomization, subjects who received cyclosporine or tacrolimus within the last 4 weeks prior to randomization and a dose of > 30 mg/day or equivalent per kg body weight in the last 4 weeks prior to randomization
	Subjects who have been treated with a dose of ≥ 1 mg per kg body weight prednisone or ≥ 30 mg/day in the last 4 weeks prior to randomization
	Ongoing treatment with cyclosporine or tacrolimus. Eligible subjects must have stopped cyclosporine and tacrolimus at least 4 weeks and antibiotics at least 1 week prior to randomization.
	Currently receiving parenteral nutrition or blood transfusions
	Planned diet change, any severe or new dietary restrictions
	Known allergies to bilberries or any other AC containing fruits
Ability to understand the treatment, willingness to comply all study requirements and ability to provide informed consent	Concurrent participation in another clinical study with investigational therapy or previous use of investigational therapy within 5 half-lives and within at least 30 days after last treatment of the experimental product prior to enrolment
	Females who are lactating or have a positive serum pregnancy test during the screening period
	Repeated and confirmed laboratory findings showing <ul style="list-style-type: none"> total bilirubin $> 2 \times$ULN unless in Gilbert's syndrome AP $> 2 \times$ULN ALT $> 2 \times$ULN serum creatinine $> 2 \times$ULN white blood cell count outside the range of 3,000-15,000 per μL platelet count $< 100,000$ per μL hemoglobin < 8g per dl or other signs of severe anemia

559

Supplementary Table 1: Detailed inclusion and exclusion criteria

560

561

562

563

564

565

566

567

568

569

570

571

Study Periods	Screening	Treatment Period				Follow-up
Visit	S	B	1	2	3	FUP
Day	-28 to -0	1 = Baseline	15± 4d	28± 4d	56± 4d	86± 4d
Subject Information and Informed Consent	x					
Demographics	x					
Medical History	x					
Update Medical History		x	x	x	x	x
In-/Exclusion Criteria	x	x				
Physical Examination	x	x	x	x	x	x
Vital Signs (pulse, blood pressure, temperature), Body Weight, Body Height ¹	x	x	x	x	x	x
Serum Laboratory Tests (Safety Lab) ²	x	x	x	x	x	x
Pregnancy Test ³	x	x	x	x	x	x
Urine analysis	x	x	x	x	x	x
Fecal Samples, stool bacteriology, C. diff.	x					
Fecal Calprotectin	x	x	x	x	x	x
Microbiota Analyses	x	x	x	x	x	x
Resting-ECG	x					
Sigmoidoscopy with 6 Biopsies and Endoscopic Mayo Subcore and Histology (Geboes Index) Recording for central reading	x				x	
Complete Mayo Score	x				x	
Partial Mayo Score (including PRO2)	x	x	x	x	x	x
Dispense Subject Diaries ⁴	x	x	x	x	x	
Collect Subject Diaries ⁴		x	x	x	x	x
Assess quality of life (SIBDQ ⁴ , EuroQoL5D)	x	x	x	x	x	x
Distribution and/or collecting of Study Medication		x	x	x	x	x (if applicable)
Concomitant Therapy	x	x	x	x	x	x
Adverse Events and Serious Adverse Events		x	x	x	x	x
¹ only at screening ² including hematology, blood chemistry ³ Screening with serum pregnancy test, other visits with urine stick test ⁴ SIBDQ = Short Inflammatory Bowel Disease Questionnaire, Patient Diary (including stool frequency, abdominal pain and general well-being) indicated in appendix						

572

573

Supplementary Table 2: Detailed study procedure description

574

575

576 **Supplementary Table 3. Individually significant associations between genus abundance and**
577 **faecal calprotectin concentrations prior to the intervention.**
578


Genus	No. samples	Slope	Lower bound	Upper bound	p	FDR
Haemophilus	53	0.259	0.114	0.405	0.000832	0.00419
Parasutterella	46	-0.221	-0.345	-0.0963	0.000931	0.00419
TF01-11	44	0.192	0.0588	0.326	0.00578	0.0173
Hungatella_A	42	0.234	0.0532	0.416	0.0122	0.024
Lachnospira	64	0.294	0.0633	0.524	0.0134	0.024
Lawsonibacter	65	-0.317	-0.602	-0.0328	0.0296	0.0435
Phascolarctobacterium	34	-0.135	-0.259	-0.011	0.0338	0.0435
An114	54	-0.231	-0.45	-0.0118	0.0393	0.0442
Anaerobutyricum	62	-0.239	-0.476	-0.00159	0.0486	0.0486

579

580

581


582 **Supplementary Figures**



583

584 **Supplementary Figure 1. Change in the concentration of faecal calprotectin throughout the**
585 **study. a.** Each small point shows the concentration of faecal calprotectin ($\mu\text{g/g}$) in placebo-
586 treated (grey) or ACRE-treated (blue) subjects at the different time points. The large circles
587 and squares show the group geometric means. The dashed and solid lines the mean slope for
588 placebo and ACRE, respectively, estimated from a linear mixed model with random slopes
589 and intercepts for the two groups. **b.** Estimated intercept for each subject from the linear
590 mixed model. **c.** Estimated slope for each subject from the linear mixed model ($p = 0.036$).

591



592

593 **Supplementary Figure 2. The positive correlation of *Haemophilus* and faecal calprotectin**
594 **persists during the intervention in placebo-treated individuals.** Each point corresponds to a
595 sample from a subject at a specific timepoint, visit 1 (circles), visit 2 (triangles), visit 3
596 (squares), follow-up (FU, +). The line shows the estimated regression slope from a linear
597 mixed model with subject as a random effect.